Vectura Fertin Pharma Laboratories
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vectura Fertin Pharma Laboratories - overview
Established
2009
Location
Singapore, -, Singapore
Primary Industry
Pharmaceuticals
About
Vectura Fertin Pharma Laboratories provides specialized laboratory services focusing on nonclinical safety assessments in aerosol sciences and inhalation toxicology for the pharmaceutical and biotechnology sectors. Vectura Fertin Pharma Laboratories specializes in nonclinical safety assessment studies, based in Singapore. Founded in 2009, the company has been operating without any known significant pivots or changes in business strategy. In January 2025, Molex, LLC, a portfolio company of Koch Equity Development, acquired Vectura Group Plc.
Vectura Fertin Pharma Laboratories specializes in nonclinical safety assessment studies, primarily focusing on aerosol sciences and inhalation toxicology. The company offers a comprehensive suite of laboratory services ranging from proof-of-concept studies to Good Laboratory Practices (GLP)-compliant studies, catering to pharmaceutical and biotechnology clients. Their core offerings include GLP inhalation toxicology studies, in vitro safety assessment assays for novel chemical entities and biologics, and a variety of in vivo disease models, such as those for emphysema and chronic obstructive pulmonary disease (COPD). Vectura Fertin Pharma Laboratories serves a diverse client base that includes pharmaceutical and biotech companies across various geographical markets, providing tailored laboratory solutions throughout the preclinical research journey.
The company operates on a model that facilitates direct business transactions with its clients, primarily through customized service agreements. These agreements encompass a range of services, including specialized studies and safety assessments, which are billed based on the specific offerings selected by the client. Vectura Fertin Pharma Laboratories’ pricing structure is designed to accommodate the unique needs of each client, allowing for flexibility in transactions. Their flagship services, focused on inhalation toxicology and safety assessments, represent core areas of revenue generation, as clients seek these specialized services to advance their product development programs effectively.
Primary Industry
Pharmaceuticals
Sub Industries
Cardiology, Pharmaceutical Research & Development
Website
www.vecturafertinpharmalabs.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Vectura Fertin Pharma Laboratories - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 41,273,283 | 44,004,427 | 45,431,211 | 44,604,611 | 43,664,842 | 28,315,296 | 29,215,237 | - | - | - |
| % Revenue Growth (YoY) | - | 6.6% | 3.2% | (1.8%) | (2.1%) | (35.2%) | 3.2% | - | - | - |
| EBITDA (USD) | 11,192,912 | 11,719,206 | 8,521,493 | 8,907,099 | 13,679,397 | 6,488,914 | 6,945,232 | - | - | - |
| Operating Income (USD) | 3,617,150 | 3,929,389 | 2,126,777 | 2,425,687 | 2,310,434 | 1,736,160 | 1,511,660 | - | - | - |
| Operating Margin | 8.8% | 8.9% | 4.7% | 5.4% | 5.3% | 6.1% | 5.2% | - | - | - |
| % EBITDA Margin | 27.1% | 26.6% | 18.8% | 20.0% | 31.3% | 22.9% | 23.8% | - | - | - |
| NET Income (USD) | 3,927,256 | 2,528,514 | 1,209,370 | 1,539,238 | 1,396,000 | 1,309,417 | 872,303 | - | - | - |
| % Net Margin | 9.5% | 5.7% | 2.7% | 3.5% | 3.2% | 4.6% | 3.0% | - | - | - |
Vectura Fertin Pharma Laboratories - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Vectura Group Plc | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.